• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Steven Yeh Explains Xipere Follow-up Findings, Learning Curves for Clinicians

Video

Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, discusses the length of Xipere's treatment benefits and potential learning curves regarding its suprachoroidal delivery mechanism.

Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, discusses the length of Xipere's treatment benefits and potential learning curves regarding its suprachoroidal delivery mechanism.

Transcript

What did the PEACHTREE study find about how long Xipere's treatment benefits last?

Following the PEACHTREE study, patients who had successfully completed the PEACHTREE trial did not need other rescue therapies—namely, other medications that were administered to patients who had flare ups of their inflammation—were subsequently enrolled into the MAGNOLIA study, which was an extension study that evaluated the durability of the medication in the suprachoroidal space. What we found was that 50% of individuals who did not need rescue therapy did not need additional rescue therapy at the 48-week time point, showing that 50% of patients showed durability signals out to nearly a year at the end of this trial.

Are there any limitations or potential disadvantages of this new method?

With this novel method of drug delivery, it's important to remember that it's a nuanced technique that's different than intravitreal injections, which is the most commonly used method of delivery into the eye. For this reason, investigators and clinicians who perform this procedure really need to go up the learning curve to understand how suprachoroidal delivery is achieved.

When physicians administer the medication with the microinjector, it's important to position the needle perpendicular to the sclera. As the medication goes into the suprachoroidal space, clinicians will feel a loss of resistance, knowing that they're in the right location. Once they achieve this learning curve, they'll be able to successfully deliver the medication for patients with noninfectious uveitis.

Related Videos
Will Shapiro
Pat Van Burkleo
Jeff Stark, MD, vice president, head of medical immunology, UCB
Robert Groves, MD
Screenshot of Raajit Rampal, MD, PhD
 Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Dr Padma Sripada, Columbia Internal Medicine
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.